{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"4","value":"3"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"6","value":"3"}]}],"title":"Including imputations for participants who died"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"4","value":"3"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"6","value":"3"}]}],"title":"Among participants who did not die"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"description":"Duration of new oxygen use was measured in days among participants who were not on oxygen at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die","dispersionType":"Inter-Quartile Range","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEDIAN","populationDescription":"The analysis population is restricted to randomized participants who were not on oxygen at baseline but who subsequently required oxygen.","reportingStatus":"POSTED","timeFrame":"Day 1 through Day 29","title":"Duration of New Oxygen Use","type":"SECONDARY","unitOfMeasure":"Days"}